{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:31:51Z","timestamp":1773293511404,"version":"3.50.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16H06530"],"award-info":[{"award-number":["16H06530"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H03334"],"award-info":[{"award-number":["18H03334"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H04915"],"award-info":[{"award-number":["21H04915"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18KT0024"],"award-info":[{"award-number":["18KT0024"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H03424"],"award-info":[{"award-number":["19H03424"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005683","name":"Kyoto University","doi-asserted-by":"publisher","award":["MIP Interdisciplinary Joint Research grant"],"award-info":[{"award-number":["MIP Interdisciplinary Joint Research grant"]}],"id":[{"id":"10.13039\/501100005683","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJSP2110"],"award-info":[{"award-number":["JPMJSP2110"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004696","name":"National Bioscience Database Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004696","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009023","name":"Precursory Research for Embryonic Science and Technology","doi-asserted-by":"publisher","award":["JPMJPR1942"],"award-info":[{"award-number":["JPMJPR1942"]}],"id":[{"id":"10.13039\/501100009023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20gm5010003"],"award-info":[{"award-number":["JP20gm5010003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Elucidating the modes of action (MoAs) of drugs and drug candidate compounds is critical for guiding translation from drug discovery to clinical application. Despite the development of several data-driven approaches for predicting chemical\u2013disease associations, the molecular cues that organize the epigenetic landscape of drug responses remain poorly understood.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>With the use of a computational method, we attempted to elucidate the epigenetic landscape of drug responses, in terms of transcription factors (TFs), through large-scale ChIP-seq data analyses. In the algorithm, we systematically identified TFs that regulate the expression of chemically induced genes by integrating transcriptome data from chemical induction experiments and almost all publicly available ChIP-seq data (consisting of 13,558 experiments). By relating the resultant chemical\u2013TF associations to a repository of associated proteins for a wide range of diseases, we made a comprehensive prediction of chemical\u2013TF\u2013disease associations, which could then be used to account for drug MoAs. Using this approach, we predicted that: (1) cisplatin promotes the anti-tumor activity of TP53 family members but suppresses the cancer-inducing function of MYCs; (2) inhibition of RELA and E2F1 is pivotal for leflunomide to exhibit antiproliferative activity; and (3) CHD8 mediates valproic acid-induced autism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our proposed approach has the potential to elucidate the MoAs for both approved drugs and candidate compounds from an epigenetic perspective, thereby revealing new therapeutic targets, and to guide the discovery of unexpected therapeutic effects, side effects, and novel targets and actions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-022-04571-8","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T13:10:05Z","timestamp":1643029805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Epigenetic landscape of drug responses revealed through large-scale ChIP-seq data analyses"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1075-4936","authenticated-orcid":false,"given":"Zhaonan","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6500-4692","authenticated-orcid":false,"given":"Michio","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2279-8773","authenticated-orcid":false,"given":"Yoshihiro","family":"Yamanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4767-3259","authenticated-orcid":false,"given":"Shinya","family":"Oki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"issue":"6","key":"4571_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.tcm.2009.12.006","volume":"19","author":"Y Etzion","year":"2009","unstructured":"Etzion Y, Muslin AJ. The application of phenotypic high-throughput screening techniques to cardiovascular research. Trends Cardiovasc Med. 2009;19(6):207\u201312. https:\/\/doi.org\/10.1016\/j.tcm.2009.12.006.","journal-title":"Trends Cardiovasc Med"},{"issue":"7","key":"4571_CR2","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/1087057108320545","volume":"13","author":"J Gao","year":"2008","unstructured":"Gao J, Xu Y, Yang Y, et al. Identification of upregulators of human ATP-binding cassette transporter A1 via high-throughput screening of a synthetic and natural compound library. J Biomol Screen. 2008;13(7):648\u201356. https:\/\/doi.org\/10.1177\/1087057108320545.","journal-title":"J Biomol Screen"},{"issue":"5441","key":"4571_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.286.5441.971","volume":"286","author":"TU Mayer","year":"1999","unstructured":"Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999;286(5441):971\u20134. https:\/\/doi.org\/10.1126\/science.286.5441.971.","journal-title":"Science"},{"issue":"1","key":"4571_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13321-018-0325-4","volume":"11","author":"N Bosc","year":"2019","unstructured":"Bosc N, Atkinson F, Felix E, Gaulton A, Hersey A, Leach AR. Large scale comparison of QSAR and conformal prediction methods and their applications in drug discovery. J Cheminform. 2019;11(1):4. https:\/\/doi.org\/10.1186\/s13321-018-0325-4.","journal-title":"J Cheminform"},{"issue":"2","key":"4571_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2174\/157340912800492357","volume":"8","author":"DT Stanton","year":"2012","unstructured":"Stanton DT. QSAR and QSPR model interpretation using partial least squares (PLS) analysis. Curr Comput Aided Drug Des. 2012;8(2):107\u201327. https:\/\/doi.org\/10.2174\/157340912800492357.","journal-title":"Curr Comput Aided Drug Des"},{"issue":"5\u20136","key":"4571_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/10629360310001624015","volume":"14","author":"AK Saxena","year":"2003","unstructured":"Saxena AK, Prathipati P. Comparison of MLR, PLS and GA-MLR in QSAR analysis. SAR QSAR Environ Res. 2003;14(5\u20136):433\u201345. https:\/\/doi.org\/10.1080\/10629360310001624015.","journal-title":"SAR QSAR Environ Res"},{"issue":"5","key":"4571_CR7","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3390\/ijms10051978","volume":"10","author":"P Liu","year":"2009","unstructured":"Liu P, Long W. Current mathematical methods used in QSAR\/QSPR studies. Int J Mol Sci. 2009;10(5):1978\u201398. https:\/\/doi.org\/10.3390\/ijms10051978.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4571_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.copbio.2009.08.003","volume":"20","author":"P Kolb","year":"2009","unstructured":"Kolb P, Ferreira RS, Irwin JJ, Shoichet BK. Docking and chemoinformatic screens for new ligands and targets. Curr Opin Biotechnol. 2009;20(4):429\u201336. https:\/\/doi.org\/10.1016\/j.copbio.2009.08.003.","journal-title":"Curr Opin Biotechnol"},{"issue":"19","key":"4571_CR9","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1093\/bioinformatics\/btn409","volume":"24","author":"L Jacob","year":"2008","unstructured":"Jacob L, Vert JP. Protein-ligand interaction prediction: an improved chemogenomics approach. Bioinformatics. 2008;24(19):2149\u201356. https:\/\/doi.org\/10.1093\/bioinformatics\/btn409.","journal-title":"Bioinformatics"},{"issue":"7270","key":"4571_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature08506","volume":"462","author":"MJ Keiser","year":"2009","unstructured":"Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462(7270):175\u201381. https:\/\/doi.org\/10.1038\/nature08506.","journal-title":"Nature"},{"issue":"3","key":"4571_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/psp4.12172","volume":"6","author":"J Fang","year":"2017","unstructured":"Fang J, Cai C, Wang Q, Lin P, Zhao Z, Cheng F. Systems pharmacology-based discovery of natural products for precision oncology through targeting cancer mutated genes. CPT Pharmacometr Syst Pharmacol. 2017;6(3):177\u201387. https:\/\/doi.org\/10.1002\/psp4.12172.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"12","key":"4571_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s13073-014-0095-1","volume":"6","author":"J Cheng","year":"2014","unstructured":"Cheng J, Yang L, Kumar V, Agarwal P. Systematic evaluation of connectivity map for disease indications. Genome Med. 2014;6(12):540. https:\/\/doi.org\/10.1186\/s13073-014-0095-1.","journal-title":"Genome Med"},{"key":"4571_CR13","doi-asserted-by":"publisher","DOI":"10.1142\/9789814447973_0002","author":"J Cheng","year":"2013","unstructured":"Cheng J, Xie Q, Kumar V, et al. Evaluation of analytical methods for connectivity map data. Pac Symp Biocomput. 2013. https:\/\/doi.org\/10.1142\/9789814447973_0002.","journal-title":"Pac Symp Biocomput"},{"issue":"96","key":"4571_CR14","doi-asserted-by":"publisher","first-page":"96ra76","DOI":"10.1126\/scitranslmed.3002648","volume":"3","author":"JT Dudley","year":"2011","unstructured":"Dudley JT, Sirota M, Shenoy M, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med. 2011;3(96):96ra76. https:\/\/doi.org\/10.1126\/scitranslmed.3002648.","journal-title":"Sci Transl Med"},{"issue":"8","key":"4571_CR15","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/cas.12183","volume":"104","author":"T Kosaka","year":"2013","unstructured":"Kosaka T, Nagamatsu G, Saito S, Oya M, Suda T, Horimoto K. Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming. Cancer Sci. 2013;104(8):1017\u201326. https:\/\/doi.org\/10.1111\/cas.12183.","journal-title":"Cancer Sci"},{"issue":"20","key":"4571_CR16","doi-asserted-by":"publisher","first-page":"5690","DOI":"10.1158\/0008-5472.CAN-13-3540","volume":"74","author":"V van Noort","year":"2014","unstructured":"van Noort V, Scholch S, Iskar M, et al. Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling. Cancer Res. 2014;74(20):5690\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3540.","journal-title":"Cancer Res"},{"issue":"Database issue","key":"4571_CR17","doi-asserted-by":"publisher","first-page":"D921\u20137","DOI":"10.1093\/nar\/gku955","volume":"43","author":"Y Igarashi","year":"2015","unstructured":"Igarashi Y, Nakatsu N, Yamashita T, et al. Open TG-GATEs: a large-scale toxicogenomics database. Nucleic Acids Res. 2015;43(Database issue):D921-7. https:\/\/doi.org\/10.1093\/nar\/gku955.","journal-title":"Nucleic Acids Res"},{"issue":"5795","key":"4571_CR18","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929\u201335. https:\/\/doi.org\/10.1126\/science.1132939.","journal-title":"Science"},{"issue":"Web Server issu","key":"4571_CR19","doi-asserted-by":"publisher","first-page":"W449\u201360","DOI":"10.1093\/nar\/gku476","volume":"42","author":"Q Duan","year":"2014","unstructured":"Duan Q, Flynn C, Niepel M, et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res. 2014;42(Web Server issue):W449-60. https:\/\/doi.org\/10.1093\/nar\/gku476.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"4571_CR20","doi-asserted-by":"publisher","first-page":"D948","DOI":"10.1093\/nar\/gky868","volume":"47","author":"AP Davis","year":"2019","unstructured":"Davis AP, Grondin CJ, Johnson RJ, et al. The comparative toxicogenomics database: update 2019. Nucleic Acids Res. 2019;47(D1):D948\u201354. https:\/\/doi.org\/10.1093\/nar\/gky868.","journal-title":"Nucleic Acids Res"},{"key":"4571_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41540-018-0061-4","volume":"4","author":"S Wilson","year":"2018","unstructured":"Wilson S, Filipp FV. A network of epigenomic and transcriptional cooperation encompassing an epigenomic master regulator in cancer. NPJ Syst Biol Appl. 2018;4:24. https:\/\/doi.org\/10.1038\/s41540-018-0061-4.","journal-title":"NPJ Syst Biol Appl"},{"issue":"12","key":"4571_CR22","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/s41416-020-01077-z","volume":"123","author":"M Ameratunga","year":"2020","unstructured":"Ameratunga M, Brana I, Bono P, et al. First-in-human phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. Br J Cancer. 2020;123(12):1730\u20136. https:\/\/doi.org\/10.1038\/s41416-020-01077-z.","journal-title":"Br J Cancer"},{"issue":"30","key":"4571_CR23","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","volume":"36","author":"J Lewin","year":"2018","unstructured":"Lewin J, Soria JC, Stathis A, et al. Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol. 2018;36(30):3007\u201314. https:\/\/doi.org\/10.1200\/JCO.2018.78.2292.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4571_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13148-019-0775-1","volume":"11","author":"CM van Tilburg","year":"2019","unstructured":"van Tilburg CM, Milde T, Witt R, et al. Phase I\/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. Clin Epigenet. 2019;11(1):188. https:\/\/doi.org\/10.1186\/s13148-019-0775-1.","journal-title":"Clin Epigenet"},{"issue":"4","key":"4571_CR25","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","volume":"69","author":"ZQ Ning","year":"2012","unstructured":"Ning ZQ, Li ZB, Newman MJ, et al. Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69(4):901\u20139. https:\/\/doi.org\/10.1007\/s00280-011-1766-x.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4571_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13619-015-0015-x","volume":"4","author":"F Fontaine","year":"2015","unstructured":"Fontaine F, Overman J, Fran\u00e7ois M. Pharmacological manipulation of transcription factor protein-protein interactions: opportunities and obstacles. Cell Regen. 2015;4(1):2. https:\/\/doi.org\/10.1186\/s13619-015-0015-x.","journal-title":"Cell Regen"},{"issue":"12","key":"4571_CR27","doi-asserted-by":"publisher","first-page":"e46255","DOI":"10.15252\/embr.201846255","volume":"19","author":"S Oki","year":"2018","unstructured":"Oki S, Ohta T, Shioi G, et al. ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq data. EMBO Rep. 2018;19(12):e46255. https:\/\/doi.org\/10.15252\/embr.201846255.","journal-title":"EMBO Rep"},{"issue":"D1","key":"4571_CR28","doi-asserted-by":"publisher","first-page":"D845","DOI":"10.1093\/nar\/gkz1021","volume":"48","author":"J Pinero","year":"2020","unstructured":"Pinero J, Ramirez-Anguita JM, Sauch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48(D1):D845\u201355. https:\/\/doi.org\/10.1093\/nar\/gkz1021.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"4571_CR29","doi-asserted-by":"publisher","first-page":"D355\u201360","DOI":"10.1093\/nar\/gkp896","volume":"38","author":"M Kanehisa","year":"2010","unstructured":"Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010;38(Database issue):D355-60. https:\/\/doi.org\/10.1093\/nar\/gkp896.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"4571_CR30","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/iju.12146","volume":"20","author":"K Takayama","year":"2013","unstructured":"Takayama K, Inoue S. Transcriptional network of androgen receptor in prostate cancer progression. Int J Urol. 2013;20(8):756\u201368. https:\/\/doi.org\/10.1111\/iju.12146.","journal-title":"Int J Urol"},{"issue":"6","key":"4571_CR31","first-page":"1980","volume":"9","author":"EV Jensen","year":"2003","unstructured":"Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003;9(6):1980\u20139.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"4571_CR32","doi-asserted-by":"publisher","first-page":"26245","DOI":"10.18632\/oncotarget.15441","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang X, Dasari S, Nowakowski GS, et al. Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. Oncotarget. 2017;8(16):26245\u201355. https:\/\/doi.org\/10.18632\/oncotarget.15441.","journal-title":"Oncotarget"},{"issue":"6","key":"4571_CR33","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1073\/pnas.95.6.3003","volume":"95","author":"VM Richon","year":"1998","unstructured":"Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998;95(6):3003\u20137. https:\/\/doi.org\/10.1073\/pnas.95.6.3003.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7327","key":"4571_CR34","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067\u201373. https:\/\/doi.org\/10.1038\/nature09504.","journal-title":"Nature"},{"key":"4571_CR35","doi-asserted-by":"publisher","first-page":"12846","DOI":"10.1038\/ncomms12846","volume":"7","author":"Z Wang","year":"2016","unstructured":"Wang Z, Monteiro CD, Jagodnik KM, et al. Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd. Nat Commun. 2016;7:12846. https:\/\/doi.org\/10.1038\/ncomms12846.","journal-title":"Nat Commun"},{"issue":"1","key":"4571_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0027-5107(78)90014-3","volume":"51","author":"HN Fraval","year":"1978","unstructured":"Fraval HN, Rawlings CJ, Roberts JJ. Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus. Mutat Res. 1978;51(1):121\u201332. https:\/\/doi.org\/10.1016\/0027-5107(78)90014-3.","journal-title":"Mutat Res"},{"issue":"2","key":"4571_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4143\/crt.2016.572","volume":"50","author":"J Guo","year":"2018","unstructured":"Guo J, Xu B, Han Q, et al. Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res Treat. 2018;50(2):445\u201360. https:\/\/doi.org\/10.4143\/crt.2016.572.","journal-title":"Cancer Res Treat"},{"issue":"9","key":"4571_CR38","first-page":"2133","volume":"53","author":"DL Evans","year":"1993","unstructured":"Evans DL, Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res. 1993;53(9):2133\u20139.","journal-title":"Cancer Res"},{"issue":"13","key":"4571_CR39","first-page":"3077","volume":"59","author":"KM Henkels","year":"1999","unstructured":"Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res. 1999;59(13):3077\u201383.","journal-title":"Cancer Res"},{"issue":"5","key":"4571_CR40","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026062","volume":"6","author":"BJ Aubrey","year":"2016","unstructured":"Aubrey BJ, Strasser A, Kelly GL. Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb Perspect Med. 2016;6(5): a026062. https:\/\/doi.org\/10.1101\/cshperspect.a026062.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"4571_CR41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ccr.2005.02.019","volume":"7","author":"ER Flores","year":"2005","unstructured":"Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 2005;7(4):363\u201373. https:\/\/doi.org\/10.1016\/j.ccr.2005.02.019.","journal-title":"Cancer Cell"},{"issue":"1","key":"4571_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22\u201335. https:\/\/doi.org\/10.1016\/j.cell.2012.03.003.","journal-title":"Cell"},{"issue":"11","key":"4571_CR43","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0149-2918(00)86732-6","volume":"21","author":"MM Goldenberg","year":"1999","unstructured":"Goldenberg MM. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. Clin Ther. 1999;21(11):1837\u201352. https:\/\/doi.org\/10.1016\/S0149-2918(00)86732-6.","journal-title":"Clin Ther"},{"issue":"8","key":"4571_CR44","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/1529-0131(200008)43:8<1820::AID-ANR18>3.0.CO;2-D","volume":"43","author":"MC Kraan","year":"2000","unstructured":"Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum. 2000;43(8):1820\u201330. https:\/\/doi.org\/10.1002\/1529-0131(200008)43:8%3c1820::AID-ANR18%3e3.0.CO;2-D.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4571_CR45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/BF01796261","volume":"44","author":"HM Cherwinski","year":"1995","unstructured":"Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ransom JT. Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res. 1995;44(8):317\u201322. https:\/\/doi.org\/10.1007\/BF01796261.","journal-title":"Inflamm Res"},{"issue":"6 pt 1","key":"4571_CR46","first-page":"1016","volume":"14","author":"WW Cao","year":"1995","unstructured":"Cao WW, Kao PN, Chao AC, Gardner P, Ng J, Morris RE. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. J Heart Lung Transplant. 1995;14(6 pt 1):1016\u201330.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"4571_CR47","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1021\/bi952168g","volume":"35","author":"JP Davis","year":"1996","unstructured":"Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 1996;35(4):1270\u20133. https:\/\/doi.org\/10.1021\/bi952168g.","journal-title":"Biochemistry"},{"key":"4571_CR48","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.omto.2019.04.006","volume":"14","author":"R Buettner","year":"2019","unstructured":"Buettner R, Morales C, Wu X, et al. Leflunomide synergizes with gemcitabine in growth inhibition of PC cells and impairs c-Myc signaling through PIM kinase targeting. Mol Ther Oncolytics. 2019;14:149\u201358. https:\/\/doi.org\/10.1016\/j.omto.2019.04.006.","journal-title":"Mol Ther Oncolytics"},{"issue":"3","key":"4571_CR49","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/sj.leu.2404922","volume":"22","author":"I Ringshausen","year":"2008","unstructured":"Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T. The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia. 2008;22(3):635\u20138. https:\/\/doi.org\/10.1038\/sj.leu.2404922.","journal-title":"Leukemia"},{"issue":"2","key":"4571_CR50","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3892\/ol.2019.11241","volume":"19","author":"LN Peng","year":"2020","unstructured":"Peng LN, Deng XY, Gan XX, et al. Targeting of TLE3 by miR-3677 in human breast cancer promotes cell proliferation, migration and invasion. Oncol Lett. 2020;19(2):1409\u201317. https:\/\/doi.org\/10.3892\/ol.2019.11241.","journal-title":"Oncol Lett"},{"issue":"1","key":"4571_CR51","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13046-016-0426-8","volume":"35","author":"RW Yang","year":"2016","unstructured":"Yang RW, Zeng YY, Wei WT, et al. TLE3 represses colorectal cancer proliferation by inhibiting MAPK and AKT signaling pathways. J Exp Clin Cancer Res. 2016;35(1):152. https:\/\/doi.org\/10.1186\/s13046-016-0426-8.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4571_CR52","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1038\/s41467-019-12163-z","volume":"10","author":"C Liang","year":"2019","unstructured":"Liang C, Li J, Lu C, et al. HIF1\u03b1 inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis. Nat Commun. 2019;10(1):4579. https:\/\/doi.org\/10.1038\/s41467-019-12163-z.","journal-title":"Nat Commun"},{"issue":"2","key":"4571_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cells5020015","volume":"5","author":"MH Park","year":"2016","unstructured":"Park MH, Hong JT. Roles of NF-kappaB in cancer and inflammatory diseases and their therapeutic approaches. Cells. 2016;5(2):15. https:\/\/doi.org\/10.3390\/cells5020015.","journal-title":"Cells"},{"issue":"11","key":"4571_CR54","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nrc2696","volume":"9","author":"HZ Chen","year":"2009","unstructured":"Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009;9(11):785\u201397. https:\/\/doi.org\/10.1038\/nrc2696.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4571_CR55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0192-0561(85)90003-7","volume":"7","author":"RR Bartlett","year":"1985","unstructured":"Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity\u2014I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol. 1985;7(1):7\u201318. https:\/\/doi.org\/10.1016\/0192-0561(85)90003-7.","journal-title":"Int J Immunopharmacol"},{"issue":"5","key":"4571_CR56","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/0092-8674(86)90346-6","volume":"46","author":"R Sen","year":"1986","unstructured":"Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986;46(5):705\u201316. https:\/\/doi.org\/10.1016\/0092-8674(86)90346-6.","journal-title":"Cell"},{"issue":"6","key":"4571_CR57","doi-asserted-by":"publisher","first-page":"9125","DOI":"10.3892\/mmr.2017.7755","volume":"16","author":"A Ren","year":"2017","unstructured":"Ren A, Fu G, Qiu Y, Cui H. Leflunomide inhibits proliferation and tumorigenesis of oral squamous cell carcinoma. Mol Med Rep. 2017;16(6):9125\u201330. https:\/\/doi.org\/10.3892\/mmr.2017.7755.","journal-title":"Mol Med Rep"},{"key":"4571_CR58","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.lfs.2015.10.003","volume":"141","author":"HI Bahr","year":"2015","unstructured":"Bahr HI, Toraih EA, Mohammed EA, Mohammad HM, Ali EA, Zaitone SA. Chemopreventive effect of leflunomide against Ehrlich\u2019s solid tumor grown in mice: effect on EGF and EGFR expression and tumor proliferation. Life Sci. 2015;141:193\u2013201. https:\/\/doi.org\/10.1016\/j.lfs.2015.10.003.","journal-title":"Life Sci"},{"issue":"8","key":"4571_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071555","volume":"8","author":"S Zhu","year":"2013","unstructured":"Zhu S, Yan X, Xiang Z, Ding HF, Cui H. Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo. PLoS ONE. 2013;8(8): e71555. https:\/\/doi.org\/10.1371\/journal.pone.0071555.","journal-title":"PLoS ONE"},{"issue":"10","key":"4571_CR60","doi-asserted-by":"publisher","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","volume":"17","author":"M Romoli","year":"2019","unstructured":"Romoli M, Mazzocchetti P, D\u2019Alonzo R, et al. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol. 2019;17(10):926\u201346. https:\/\/doi.org\/10.2174\/1570159X17666181227165722.","journal-title":"Curr Neuropharmacol"},{"issue":"24","key":"4571_CR61","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M Gottlicher","year":"2001","unstructured":"Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20(24):6969\u201378. https:\/\/doi.org\/10.1093\/emboj\/20.24.6969.","journal-title":"EMBO J"},{"issue":"1","key":"4571_CR62","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13046-019-1160-9","volume":"38","author":"T Lin","year":"2019","unstructured":"Lin T, Ren Q, Zuo W, et al. Valproic acid exhibits anti-tumor activity selectively against EGFR\/ErbB2\/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs. J Exp Clin Cancer Res. 2019;38(1):150. https:\/\/doi.org\/10.1186\/s13046-019-1160-9.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"4571_CR63","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3325\/cmj.2017.58.349","volume":"58","author":"XJ Ma","year":"2017","unstructured":"Ma XJ, Wang YS, Gu WP, Zhao X. The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells. Croat Med J. 2017;58(5):349\u201357. https:\/\/doi.org\/10.3325\/cmj.2017.58.349.","journal-title":"Croat Med J"},{"issue":"6","key":"4571_CR64","first-page":"2231","volume":"31","author":"Y Chen","year":"2011","unstructured":"Chen Y, Tsai YH, Tseng SH. Combined valproic acid and celecoxib treatment induced synergistic cytotoxicity and apoptosis in neuroblastoma cells. Anticancer Res. 2011;31(6):2231\u20139.","journal-title":"Anticancer Res"},{"issue":"6","key":"4571_CR65","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.molonc.2012.09.005","volume":"6","author":"SS Nair","year":"2012","unstructured":"Nair SS, Kumar R. Chromatin remodeling in cancer: a gateway to regulate gene transcription. Mol Oncol. 2012;6(6):611\u20139. https:\/\/doi.org\/10.1016\/j.molonc.2012.09.005.","journal-title":"Mol Oncol"},{"issue":"3","key":"4571_CR66","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cell.2012.03.028","volume":"149","author":"ME Talkowski","year":"2012","unstructured":"Talkowski ME, Rosenfeld JA, Blumenthal I, et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell. 2012;149(3):525\u201337. https:\/\/doi.org\/10.1016\/j.cell.2012.03.028.","journal-title":"Cell"},{"issue":"7397","key":"4571_CR67","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nature10989","volume":"485","author":"BJ O\u2019Roak","year":"2012","unstructured":"O\u2019Roak BJ, Vives L, Girirajan S, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012;485(7397):246\u201350. https:\/\/doi.org\/10.1038\/nature10989.","journal-title":"Nature"},{"issue":"7622","key":"4571_CR68","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nature19357","volume":"537","author":"Y Katayama","year":"2016","unstructured":"Katayama Y, Nishiyama M, Shoji H, et al. CHD8 haploinsufficiency results in autistic-like phenotypes in mice. Nature. 2016;537(7622):675\u20139. https:\/\/doi.org\/10.1038\/nature19357.","journal-title":"Nature"},{"issue":"16","key":"4571_CR69","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jama.2013.2270","volume":"309","author":"J Christensen","year":"2013","unstructured":"Christensen J, Gronborg TK, Sorensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309(16):1696\u2013703. https:\/\/doi.org\/10.1001\/jama.2013.2270.","journal-title":"JAMA"},{"issue":"D1","key":"4571_CR70","doi-asserted-by":"publisher","first-page":"D87","DOI":"10.1093\/nar\/gkz1001","volume":"48","author":"O Fornes","year":"2020","unstructured":"Fornes O, Castro-Mondragon JA, Khan A, et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2020;48(D1):D87-92. https:\/\/doi.org\/10.1093\/nar\/gkz1001.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"4571_CR71","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1101\/gr.169508.113","volume":"24","author":"PJ Balwierz","year":"2014","unstructured":"Balwierz PJ, Pachkov M, Arnold P, Gruber AJ, Zavolan M, van Nimwegen E. ISMARA: automated modeling of genomic signals as a democracy of regulatory motifs. Genome Res. 2014;24(5):869\u201384. https:\/\/doi.org\/10.1101\/gr.169508.113.","journal-title":"Genome Res"},{"issue":"4","key":"4571_CR72","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nmeth.3772","volume":"13","author":"EG Gusmao","year":"2016","unstructured":"Gusmao EG, Allhoff M, Zenke M, Costa IG. Analysis of computational footprinting methods for DNase sequencing experiments. Nat Methods. 2016;13(4):303\u20139. https:\/\/doi.org\/10.1038\/nmeth.3772.","journal-title":"Nat Methods"},{"issue":"51","key":"4571_CR73","doi-asserted-by":"publisher","first-page":"21521","DOI":"10.1073\/pnas.0904863106","volume":"106","author":"Z Ouyang","year":"2009","unstructured":"Ouyang Z, Zhou Q, Wong WH. ChIP-Seq of transcription factors predicts absolute and differential gene expression in embryonic stem cells. Proc Natl Acad Sci U S A. 2009;106(51):21521\u20136. https:\/\/doi.org\/10.1073\/pnas.0904863106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"4571_CR74","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26(6):841\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btq033.","journal-title":"Bioinformatics"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-022-04571-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-022-04571-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-022-04571-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T13:10:30Z","timestamp":1643029830000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-022-04571-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4571"],"URL":"https:\/\/doi.org\/10.1186\/s12859-022-04571-8","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"28 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Content for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}